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Abstract 
Background: Factor XIII (FXIII) is a heterotetramer consisting of two 
subunits, FXIII-A and FXIII-B. Several common gene variations were 
observed in the FXIII-A gene with an obvious ethnic difference. This study 
assessed the prevalence of A614T as a common FXIII-A gene variation 
among Iranian patients with FXIII deficiency (FXIIID).  
Materials and Methods: This study was conducted on eighty Iranian 
unrelated individuals with FXIIID. Genotype analysis for FXIII-A A614T 
gene variation was performed for all individuals.  
Results: Molecular analysis of these Iranian populations revealed that all 
studied patients were homozygous for the T allele at codon 204 of the FXIII-
A1 subunit.  
Conclusion: Present of T allele at codon 204 of FXIII-A1 subunit among all 
study population can be suggestive of founder effect. 
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Introduction 
Coagulation factor XIII (FXIII) or fibrin stabilizing 
factor is a zymogen composed of two A-subunits and 
two B- subunits that are held together no covalently in 
a tetrameric form (1). The gene coding FXIII-A 
subunit consists of 15 exons, covers a genomic region 
of 160 kb, and maps to the 6p24-25 chromosomal 
region. This subunit consists of 731 amino acids and 
characterized by 5 domains including the activation 
peptide (residues of 1-37), β-sandwich (residues of 
38-183), the central domain of catalytic core region 
(residues 184-515), β-barrel 1, and 2 (residues 516- 
627 and residues 628-731, respectively) (2, 3). The 
gene coding  FXIII-B subunit located on 1q31-32 
covers a 28 kb genomic region and compromise of 12 
exons which are separated by 11 introns. This subunit 
consists of 10 tandem repeats named sushi domains 
(2, 3). The active form of factor cross-links the fibrin 
monomer and stabilizes the fibrin clot during the final 
stage of the coagulation cascade. In addition, FXIII 
has an essential role in wound healing, angiogenesis, 
and maintaining the pregnancy (1, 4, 5).  
Until now, a considerable number of 
polymorphisms have been identified in FXIII-A 
subunits and the most common of them are Val34Leu 
in exon 2, Tyr204Phe in exon 5, 
Pro(CCA)331(CCC)Pro in exon 8, Pro564Leu, Glu 
(GAA)567Glu(GAG) in exon 12, Val650Ile, and 
Glu651Gln in exon 14. Also, in the factor XIII-B 
subunit two common polymorphisms were reported, 
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His95Arg and C29759G change in intron K29756 (1-
5, 8, 9). Studies on the structural and functional 
effects of these mutations lead to a better 
understanding of the causes of and accurate diagnosis 
of this disorder. Thus, our study aims to evaluate one 




This descriptive study was conducted on eighty 
unrelated Iranian patients with FXIII deficiency 
(FXIIID). All participants gave informed by written 
consent according to the protocol approved by the 
local medical ethics committee.  
Blood sample from each patient was collected 
in Ethylene-diaminetetraacetic Acid (EDTA) 
anticoagulant tube.  Blood specimens were lysed with 
sodium dodecyl sulfate (SDS) and genomic DNA of 
each sample was isolated from the leucocytes 
according to the standard protocol. DNA was purified 
using phenol-chloroform and ethanol precipitation. 
The quality and quantity of obtained DNA were 
determined through spectrophotometry and also 
using agarose gel electrophoresis. 
After DNA extraction, genotyping of FXIII-A 
A614T gene variation was performed by polymerase 
chain reaction amplification of genomic DNA 
followed by restriction enzyme digestion (PCR-
RFLP) (Table 1). Primer and DNA sequences were 
selected from reports published previously (9). For all 
PCR amplification, positive control DNA samples of 
known genotype were included as well as a negative 
control without template DNA. 
 
Results 
This descriptive study was conducted on eighty 
patients with severe FXIID from same number of 
unrelated families. Among our patients, 52.5% (n: 42) 
were male and 47.5% (38) were female and the mean 
age of them was 26±3 years. In all patients, genetic 
analysis revealed that homozygous for T allele at 
codon 204 of FXIII-A1 subunit. In every case, the 
sequencing results agreed with the PCR-RFLP 
genotyping result. 
 
Fig. 1.  Results of polymerase chain reaction-
restriction fragment length polymorphism (PCR-
RFLP) of factor XIII-A A614T gene variation among 
Iranian patients with severe congenital factor XIII 
deficiency. 
1- 50bp ladder, 2- 113 bp undigested band, 3- Two 91 
and 22 bp band after digestion with Rsa I restriction 
enzyme. 
Table 1: Characteristics of used primers and restriction enzymes. 
 













Rsa I 91, 22  
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Discussion 
FXIII is a coagulation factor with multiple intra- and 
extracellular functions (1, 9, 10). Several studies 
revealed that there are five common gene variations in 
the FXIII-A gene including Val34Leu, Tyr204Phe, 
Pro564Leu, Glu567Glu, and Glu651Gln (1-5). These 
common gene variations show a significant difference 
in various ethnicities. No comprehensive study was 
performed in Iranian patients with severe FXIIID to 
asses’ prevalence of these polymorphisms among this 
population. 
After careful selection of the study population, 
we chose A614T as a common mutation of FXIII-A. 
We found that all patients were homozygous for the T 
allele at codon 204 of the FXIII-A1 subunit.  
We previously found that all of these patients 
were homozygote for c559t mutation in the FXIII-A 
subunit (4, 10, 11). This mutation of a disease-causing 
mutation and cause severe FXIIID in Iranian patients. 
These two findings are a sign of founder effect in 
these individuals but further studies are required for 
confirmation of this issue. A few studies were 
performed on Iranian patients to the determined 
prevalence of this common polymorphism. Jeddi-
Tehrani et al. were found that these common FXIII-A 
gene variations with a frequency of 84% in women 
with miscarriage and with a prevalence of 48% in 
healthy Iranian individuals (12). Their finding showed 
that this FXIII-A polymorphism is common among 
Iranian patients such other ethnicities in the world. A 
comparison with the results of the Jeddi-Tehrani et al. 
study it seems that all of our patients were inherited 
this common FXIII-A gene variation similarly and 
further studies on FXIII-A short tandem repeat (STR) 
can confirm this issue that c559t mutation in FXIII-A 
is the result from a founder effect. Meanwhile, 
investigation of other FXIII-A common 
polymorphisms such as  Val34Leu in exon 2, 
Pro(CCA)331(CCC)Pro in exon 8, Pro564Leu, Glu 
(GAA)567Glu(GAG) in exon 12 as well as Val650Ile 
and Glu651Gln in exon 14 can be used for 
confirmation of founder effect in these patients (1, 13, 
14). 
Conclusion 
The presence of a similar single nucleotide 
polymorphism (SNP) in all of the study population 
unlike the normal Iranian population can be 
suggestive of the founder effect but further 
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